Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses And Other Current Liabilities

v3.20.2
Accrued Expenses And Other Current Liabilities
 9 Months Ended
Sep. 30, 2020
Accrued Liabilities and Other Liabilities [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities as of September 30, 2020 and December 31, 2019 consisted of the following: 
  As of
  September 30, 2020 December 31, 2019
Research and development expenses $ 3,381,457  $ 920,901 
Compensation and benefits 2,431,358  1,591,964 
General and administrative 705,867  360,016 
Sales and marketing 142,000  120,056 
Sales returns and allowances 1,520,716  2,284,175 
Medicaid rebates 93,701  118,271 
Lease liability, current 448,659  155,815 
Other 86,964  89,054 
Total accrued expenses and other current liabilities $ 8,810,722  $ 5,640,252 
During the second quarter of 2020, the Company and an executive entered into a separation agreement in which the executive resigned his employment effective April 24, 2020. The former executive serves as an advisor to the Company's Board of Directors and will continue to serve in such role until December 2021 or until terminated by either party upon thirty days' written notice. The former executive will receive $0.8 million in severance, which will be paid over 18 months beginning when his role as advisor to the Board ends. The severance liability, which is reported in other long-term liabilities on the Company's accompanying condensed consolidated balance sheet, is $0.8 million as of September 30, 2020.